Trial record 1 of 9 for:    "Pseudomyxoma peritonei"
Previous Study | Return to List | Next Study

Results of CRS and Debulking in PMP Patients

The recruitment status of this study is unknown because the information has not been verified recently.
Verified August 2011 by Uppsala University.
Recruitment status was  Active, not recruiting
Sponsor:
Information provided by (Responsible Party):
Uppsala University
ClinicalTrials.gov Identifier:
NCT01427101
First received: August 31, 2011
Last updated: NA
Last verified: August 2011
History: No changes posted
  Purpose

The aim of this study was to compare debulking surgery and cytoreductive surgery in patients with Pseudomyxoma Peritonei with respect to efficacy and safety.


Condition
Pseudomyxoma Peritonei

Study Type: Observational
Study Design: Observational Model: Cohort
Time Perspective: Cross-Sectional
Official Title: Comparison Between Cyotreductive Surgery and Debulking Surgery in Patients With Pseudomyxoma Peritonei

Resource links provided by NLM:


Further study details as provided by Uppsala University:

Primary Outcome Measures:
  • Overall survival [ Designated as safety issue: No ]
    from treatment and forward


Secondary Outcome Measures:
  • morbidity and mortality [ Time Frame: 90 days ] [ Designated as safety issue: Yes ]
    mortality is messured during the first 90 postoperative days and morbidity during hospital stay.


Biospecimen Description:

Patients treated from 1993 are included and during these years treatment strategy has changed. The different strategies are compared but its juts one cohort of patients. No completion date are set due to that reports from other centres show that there are longtime survivers in both treatment groups.


Study Start Date: September 1993
  Eligibility

Ages Eligible for Study:   20 Years to 80 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Sampling Method:   Probability Sample
Study Population

Patients with Pseudomyxoma Peritonei, sceduled for surgical treatment at Uppsala University Hospital.

Criteria

Inclusion Criteria:

  • Patients with radiology histopathology finding of Pseudomyxoma Peritonei

Exclusion Criteria:

  • Preformance status WHO >2 and histopathology shows other origin then Pseudomyxoma Peritonei
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01427101

Sponsors and Collaborators
Uppsala University
Investigators
Principal Investigator: Haile Mahteme, MD, PhD Uppsala University
  More Information

No publications provided

Responsible Party: Uppsala University
ClinicalTrials.gov Identifier: NCT01427101     History of Changes
Other Study ID Numbers: 2007/073-PMP-Andréasson
Study First Received: August 31, 2011
Last Updated: August 31, 2011
Health Authority: Sweden: Regional Ethical Review Board

Keywords provided by Uppsala University:
Pseudomyxoma Peritonei
Cytoreductive surgery
Debulking surgery
Intraperitoneal chemotherapy

Additional relevant MeSH terms:
Pseudomyxoma Peritonei
Neoplasms
Neoplasms by Histologic Type
Neoplasms, Cystic, Mucinous, and Serous
Neoplasms, Glandular and Epithelial

ClinicalTrials.gov processed this record on October 30, 2014